Issuers will hope the outperformance continues, as consensus is now that there will be no EPS growth in Q1. Bank of America ...
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback